Spasms

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms

Retrieved on: 
Wednesday, December 7, 2022

The open IND gives Cerecin clearance to proceed with the next phase of the planned development for CER-0001 in IS.

Key Points: 
  • The open IND gives Cerecin clearance to proceed with the next phase of the planned development for CER-0001 in IS.
  • IS usually affects children under the age of 36 months and can lead to cognitive, neurologic and sensory problems.
  • The disorder is commonly treated with hormonal medications (such as adrenocorticotropic hormone and prednisolone) and vigabatrin, an anticonvulsant.
  • Cerecin’s pilot study of CER-0001 is ongoing and will have recruited the 10th and final patient by 1H 2023.

COLOR CHANGES IN EXTREMITIES WHEN COLD USUALLY NOT NORMAL, SAY MEDICAL EXPERTS

Retrieved on: 
Tuesday, September 27, 2022

REDDING, Calif., Sept. 27, 2022 /PRNewswire/ -- As the colder weather sets in, 5-10 percent of Americans will experience episodes of color changes in their fingers or toes, accompanied by spasms of throbbing pain. That response is not normal, according to the Raynaud's Association, which notes that October is Raynaud's Awareness Month.

Key Points: 
  • That response is not normal, according to the Raynaud's Association, which notes that October is Raynaud's Awareness Month.
  • Typically, the affected area turns white, blue and red over the course of the attack.
  • "I've always felt cold when others around me felt perfectly comfortable," one woman with the disorder recalled of her upbringing.
  • Kristle Lowell, a champion trampoline gymnast, said her teammates used to call her "icy toes" because of the blue color of her feet while practicing in cold gyms.

POWER REIT PROVIDES CORPORATE UPDATE

Retrieved on: 
Friday, August 12, 2022

Old Bethpage, New York, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Power REIT (NYSE-AMEX: PW and PW.PRA) (“Power REIT” or the “Trust”), with a focused “Triple Bottom Line” strategy and a commitment to people, planet, and profit, is providing information regarding its quarterly financial performance, cannabis licensing at is Michigan greenhouse property and other portfolio updates. The information provided below includes highlights from its quarterly report and current business activities as reported on its Form 10Q filed with the SEC.

Key Points: 
  • The amendment was structured to maintain the same level of straight-line accounting for rent for Power REIT.
  • Once there is more certainty around the timing of the ability of the tenant to pay rent, Power REIT will resume recognition of revenue.
  • As previously announced, Power REIT entered into a Debt Facility with initial availability of $20 million with a 5.52% fixed interest rate.
  • Additional information about Power REIT can be found on its website: www.pwreit.com
    This document includes forward-looking statements within the meaning of the U.S. securities laws.

Safe Summer Fun

Retrieved on: 
Monday, June 6, 2022

MISSION, Kan., June 6, 2022 /PRNewswire/ --(Family Features) Longer days and lighter schedules make summer perfect for relaxing, having fun outdoors and spending time with loved ones.

Key Points: 
  • MISSION, Kan., June 6, 2022 /PRNewswire/ --(Family Features) Longer days and lighter schedules make summer perfect for relaxing, having fun outdoors and spending time with loved ones.
  • As you and your family enjoy the warmth and sunshine while swimming, biking, grilling, playing on the playground and more this summer, remember these precautions from the experts at the American Heart Association.
  • On hot summer days, be alert for signs of heat illnesses, such as heat cramps, heat exhaustion or heat stroke.
  • Spending time in or around water is one of the joys of summer, but it comes with some risks.

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Retrieved on: 
Friday, May 27, 2022

A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.

Key Points: 
  • A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • Addex remains committed to our allosteric modulator approach to drug discovery and development with two clinical trials currently ongoing.
  • Addex has been conducting a placebo-controlled Phase 2b/3 pivotal clinical trial of dipraglurant in PD-LID patients since June 2021.

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Retrieved on: 
Wednesday, April 13, 2022

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.

Key Points: 
  • Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.
  • A total of 15 patients have been enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study is to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • The effects on the severity and frequency of blepharospasm signs and symptoms using objective measures, clinical ratings and patient reported outcomes will also be evaluated as secondary endpoints.

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia

Retrieved on: 
Monday, April 11, 2022

The Phase 2 randomized, double-blind, placebo-controlled study enrolled a total of 59 patients across a total of 25 study sites in the United States.

Key Points: 
  • The Phase 2 randomized, double-blind, placebo-controlled study enrolled a total of 59 patients across a total of 25 study sites in the United States.
  • Patients enrolled into the clinical study are divided evenly across four cohorts, including a low dose (150 units), mid-dose (250 units), high dose (350 units), and placebo.
  • The primary endpoint of the clinical study is to evaluate the safety of a single treatment of ABP-450 over a maximum of 20 weeks.
  • Botulinum toxin is the standard of care for the treatment of cervical dystonia, helping to improve pain, posture, and disability.

Power REIT Acquires 1.1 Million Square Foot Greenhouse for $9.35 Million

Retrieved on: 
Friday, April 1, 2022

Old Bethpage, New York, April 01, 2022 (GLOBE NEWSWIRE) -- Power REIT (NYSE-AMEX: PW and PW.PRA) (“Power REIT” or the “Trust”) today announced that it has acquired a 1,121,513 square foot Controlled Environmental Agricultural (“CEA”) greenhouse cultivation facility, and associated employee housing property in O’Neill, Nebraska (the “Property”) through a wholly owned subsidiary (“PropCo”) for $9.35 million.

Key Points: 
  • Simultaneous with the acquisition, Power REIT entered into a long-term, triple-net lease with Millennium Produce of Nebraska LLC (MillPro).
  • As part of the transaction, Power REIT has agreed to fund capital improvements to upgrade the tomato-ready cultivation facility.
  • The greenhouse has approximately one million square feet under glass and sits on approximately 86 acres with approximately 20 acres of land available for an additional 880,000 square feet of greenhouse and related space.
  • Commenting further on Power REITs acquisition, David Lesser stated, With this transaction, Power REIT doubles its greenhouse footprint.

Power REIT Announces Fourth Quarter and Full Year 2021 Results – Net Income Per Share Increased 42% Core FFO Per Common Share Increased 44%

Retrieved on: 
Friday, April 1, 2022

During the fourth quarter of 2021, the Trust reported a Quarterly FFO Per Share of $0.35.

Key Points: 
  • During the fourth quarter of 2021, the Trust reported a Quarterly FFO Per Share of $0.35.
  • Had the straight-lined rent for the Michigan property been included in the fourth quarter 2021 calculation, the incremental FFO would add approximately $0.38 per share per quarter.
  • Lesser concluded, From an earnings perspective, we increased our Core FFO per common share by 44% year over year.
  • On February 5, 2021, Power REIT closed on its Rights Offering, generating proceeds of approximately $37 million and issued an additional 1,383,394 common shares.

Power REIT Agrees to Fund Energy Efficiency Improvements at its Greenhouse in York County, Maine.

Retrieved on: 
Monday, March 21, 2022

Pursuant to the Amendment, Power REIT will fund the installation of a highly energy efficient onsite power generation and cooling system.

Key Points: 
  • Pursuant to the Amendment, Power REIT will fund the installation of a highly energy efficient onsite power generation and cooling system.
  • Combined Heat and Power (CHP), also known as cogeneration, is the production of electricity and thermal energy from a single energy source.
  • David Lesser, Chairman and CEO of Power REIT commented, These improvements to this greenhouse cultivation facility will allow Sweet Dirt to take their operations to the next level in an energy efficient manner.
  • I have a significant background focused on sustainability and energy efficiency including the benefits of distributed generation of power in the form of cogeneration.